-
US FDA approves AstraZeneca & Daiichi Sankyo’s Enhertu to treat HER2-low or HER2-ultralow metastatic breast cancer following disease progression after one or more endocrine therapies
29 Jan 2025 04:34 GMT
… business, and president and CEO, Daiichi Sankyo, said: “Enhertu continues to … also are underway.
AstraZeneca and Daiichi Sankyo entered into a global collaboration … Japan where Daiichi Sankyo maintains exclusive rights for each ADC. Daiichi Sankyo is …
-
AstraZeneca, Daiichi Sankyo bring Enhertu to HER2-ultralow setting
28 Jan 2025 20:46 GMT
-
FDA Approves AstraZeneca, Daiichi Sankyo's Enhertu For Certain Type Of Breast Cancer Patients
28 Jan 2025 15:48 GMT
… (FDA) approved AstraZeneca plc and Daiichi Sankyo’s DSNKY DSKYF Enhertu (trastuzumab … as a milestone payment to Daiichi Sankyo.
Daiichi Sankyo recognizes Enhertu sales in the …
-
AstraZeneca, Daiichi Sankyo Continue ADC Rally With Enhertu Expansion
28 Jan 2025 15:37 GMT
… label expansion of AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate Enhertu … HER2-ultralow disease. AstraZeneca and Daiichi Sankyo in Monday’s press announcement … just days after AstraZeneca and Daiichi Sankyo won another ADC approval from …
-
AstraZeneca-Daiichi Sankyo Enhertu gets USFDA approval for HER2-ultralow metastatic breast cancer
28 Jan 2025 15:20 GMT
… Business, and President and CEO, Daiichi Sankyo, said, “Enhertu continues to redefine … drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and … commercialised by AstraZeneca and Daiichi Sankyo.
Enhertu is already approved in …
-
AstraZeneca/Daiichi Sankyo’s Enhertu granted FDA approval in breast cancer
28 Jan 2025 12:33 GMT
AstraZeneca (AZ) and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has … president and chief executive officer, Daiichi Sankyo, added: “Enhertu continues to redefine …
-
Daiichi Sankyo Admits 2024 Wasn’t ‘Perfect’ but 2025 Is Starting Off With a Bang
27 Jan 2025 07:12 GMT
Daiichi Sankyo is growing rapidly thanks to … , who serves as CEO of Daiichi Sankyo, Inc., the U.S. subsidiary …
-
AstraZeneca/Daiichi Sankyo survey reveals breast cancer misconceptions in Europe
24 Jan 2025 12:50 GMT
… sponsored by AstraZeneca (AZ) and Daiichi Sankyo has revealed widespread misconceptions about … and Canada oncology business division, Daiichi Sankyo, said: “Greater public understanding of …
-
Vaccines Market to Grow by USD 193.7 Billion (2025-2029), Increased Funding for Development and New Launches Boost the Market, Report on How AI is Driving Market Transformation - Technavio
30 Jan 2025 06:40 GMT
… Biotherapeutics Co., Ltd., CSL Ltd., Daiichi Sankyo Co. Ltd., Emergent BioSolutions Inc … Biotherapeutics Co., Ltd., CSL Ltd., Daiichi Sankyo Co. Ltd., Emergent BioSolutions Inc …
-
A Total Of USD 12.7 Million Investment In New Diagnostics And Drug Development For Ntds And Malaria To Partners Including The Ohio State University, PATH, GSK And Others
30 Jan 2025 05:03 GMT
… against malaria by MMV and Daiichi Sankyo Co., Ltd.
2) Screening … Title
Hit Validation of novel Daiichi Sankyo compounds with antimalarial activity
Collaboration … for Malaria Venture (MMV) (Switzerland)
Daiichi Sankyo Co., Ltd. (Japan)
Disease
Malaria …
About
© 1995-2025